Rachel Dean, MD
Dermatology · Alexandria, LANPI 1649413881
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,490 of the $7,188 with a category attached, or 76.4%. AbbVie accounts for 89.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $2,152 and has fallen 77.1% since, to $493 in 2025.
Across 166 payments — averaging $43.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Johnson & Johnson$219
- Lilly USA, LLC$139
- Novartis$116
- Revance Therapeutics, Inc.$86
- Sanofi$64
- plus $157 from 8 others
What the payments were for
- Speaking & faculty fees$5,49076%
- Food & beverage$1,52421%
- Education$1732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 130 | $6,406 |
| Johnson & Johnson | 5 | $219 |
| Lilly USA, LLC | 7 | $139 |
| Novartis | 7 | $116 |
| Revance Therapeutics, Inc. | 2 | $86 |
| Sanofi | 4 | $64 |
| LEO Pharma Inc. | 2 | $35 |
| Galderma Laboratories, L.p. | 2 | $29 |
| Medline Industries LP | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| EPI Health, LLC | 1 | $6 |
| Pierre Fabre Pharmaceuticals, Inc. | 2 | $6 |
How this compares
$7,188 in reported general payments places this provider in the 60th percentile of 189 dermatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 96 | $358,255 |
| TremfyaGuselkumab | 24 | $323,448 |
| Taltz AutoinjectorIxekizumab | 20 | $137,838 |
| OtezlaApremilast | 25 | $122,773 |
| Humira(Cf) PenAdalimumab | 13 | $84,883 |
| Dupixent SyringeDupilumab | 12 | $42,514 |
| Fluorouracil | 46 | $2,852 |
| Fluocinonide | 46 | $1,386 |
| Ketoconazole | 88 | $1,025 |
| Azelaic Acid | 23 | $942 |
| Tretinoin | 11 | $838 |
| Econazole Nitrate | 13 | $837 |
| Metronidazole | 21 | $795 |
| Clobetasol Propionate | 33 | $788 |
| Betamethasone Dipropionate | 14 | $674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $219 | $323,44824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 189 dermatology providers in Louisiana.
Other dermatology in Alexandria
- Elizabeth LongAlexandria$36K
- George IngrishAlexandria$21K
- Katherine HolcombMetairie$411K
- William ClaiborneNew Orleans$374K
- Blair BuddenLafayette$329K
- Erin BohNew Orleans$277K
- Mara HaseltineNew Orleans$276K
- Sarah HaydelHouma$265K
- Frankie RholdonLafayette$227K
- William MassengalePrairieville$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.